A team of Stanford researchers has identified a group of small molecules that can prevent or reverse T cell exhaustion, thereby increasing the effectiveness of adoptive T cell therapies to fight cancer or chronic infections.
Psoriasis is a chronic skin inflammatory disease that affects 7.5 million people in the US and accounts for $1.2 billion in annual direct medical costs.
Researchers at Stanford have developed synthetic derivatives of a natural product, azapodophyllotoxin (AZP), that exhibit remarkable anticancer activities.